Scarica l'app Stockscreener
14.28
0.14%
-0.02
Dopo l'orario di chiusura:
14.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$14.30
Aprire:
$14.32
Volume 24 ore:
17.70M
Relative Volume:
1.88
Capitalizzazione di mercato:
$4.42B
Reddito:
$571.16M
Utile/perdita netta:
$-38.10M
Rapporto P/E:
-116.57
EPS:
-0.1225
Flusso di cassa netto:
$-48.91M
1 W Prestazione:
+0.28%
1M Prestazione:
+44.97%
6M Prestazione:
+129.58%
1 anno Prestazione:
+50.95%
Intervallo 1D:
$14.26
$14.32
Intervallo di 1 settimana:
$14.21
$14.35
Portata 52W:
$5.51
$14.36
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.28 | 4.42B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-29 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | Downgrade | TD Cowen | Buy → Hold |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Will Amicus Therapeutics Inc. stock benefit from sector rotationPortfolio Value Report & Entry Point Strategy Guides - ulpravda.ru
How Amicus Therapeutics Inc. stock performs in rising dollar environment2025 Key Highlights & Weekly High Momentum Picks - ulpravda.ru
Why retail investors pile into Amicus Therapeutics Inc. stockWatch List & Technical Buy Zone Confirmations - ulpravda.ru
Buyback Watch: Will Amicus Therapeutics Inc. stock remain a Wall Street favoriteWeekly Gains Summary & Risk Controlled Stock Alerts - ulpravda.ru
How Amicus Therapeutics Inc. stock compares to industry benchmarksSell Signal & Low Drawdown Investment Strategies - ulpravda.ru
Risk Off: Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsMarket Activity Report & Growth Focused Investment Plans - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
San Gabriel Valley Tribune - FinancialContent
Amicus Therapeutics, Inc.Common Stock (NQ: FOLD - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-EKSO, FOLD, CWAN, and JHG - The Malaysian Reserve
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
What analysts say about Amicus Therapeutics Inc stockValue Traps to Avoid & Big Gains Low Budget - earlytimes.in
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? - Finviz
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at Guggenheim - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Amicus Therapeutics Inc AM6 Stock Analysis and Forecast - earlytimes.in
Amicus Therapeutics Earnings Notes - Trefis
BioMarin's $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - FinancialContent
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
FOLD: Analyst Downgrade and Price Target Adjustments | FOLD Stoc - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by Leerink Partners - MarketBeat
Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17 - MarketScreener
Leerink Partners downgrades Amicus Therapeutics stock on BioMarin acquisition By Investing.com - Investing.com UK
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc.FOLD - The AI Journal
Voya Investment Management LLC Sells 90,062 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Amicus Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:BMRN) 2025-12-24 - Seeking Alpha
John F. Crowley: A Legacy For Rare Diseases - Oncodaily
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Is the Market Bullish or Bearish on Amicus Therapeutics Inc? - Benzinga
Published on: 2025-12-24 04:19:57 - Bollywood Helpline
Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,642 Shares - MarketBeat
Amicus Therapeutics Executive Sells Shares Under Trading Plan - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
BioMarin To Buy Amicus For $4.8 Billion - Pulse 2.0
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSECWAN), Katapult Holdings, Inc. (NasdaqKPLT), Janus Henderson Group plc (NYSEJHG), Amicus Therapeutics, Inc. (Nasdaq - GlobeNewswire Inc.
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):